For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

Bicycle Therapeutics (BCYC) announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

TMB and various biomarkers were positively associated with improved pCR and EFS in high-risk, early-stage TNBC, regardless of ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...